These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36281042)

  • 21. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
    Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
    PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Development of a New Approach for the Harmonized Multi-Sectoral and Multi-Country Cost Valuation of Services: The PECUNIA Reference Unit Cost (RUC) Templates.
    Mayer S; Berger M; Perić N; Fischer C; Konnopka A; Brodszky V; Evers SMAA; Hakkaart-van Roijen L; Ruiz Guitérrez Colosia M; Salvador-Carulla L; Park AL; Thorn J; García-Pérez L; Simon J;
    Appl Health Econ Health Policy; 2024 Nov; 22(6):783-796. PubMed ID: 39115752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
    de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
    Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.
    Menzies NA; Gomez GB; Bozzani F; Chatterjee S; Foster N; Baena IG; Laurence YV; Qiang S; Siroka A; Sweeney S; Verguet S; Arinaminpathy N; Azman AS; Bendavid E; Chang ST; Cohen T; Denholm JT; Dowdy DW; Eckhoff PA; Goldhaber-Fiebert JD; Handel A; Huynh GH; Lalli M; Lin HH; Mandal S; McBryde ES; Pandey S; Salomon JA; Suen SC; Sumner T; Trauer JM; Wagner BG; Whalen CC; Wu CY; Boccia D; Chadha VK; Charalambous S; Chin DP; Churchyard G; Daniels C; Dewan P; Ditiu L; Eaton JW; Grant AD; Hippner P; Hosseini M; Mametja D; Pretorius C; Pillay Y; Rade K; Sahu S; Wang L; Houben RMGJ; Kimerling ME; White RG; Vassall A
    Lancet Glob Health; 2016 Nov; 4(11):e816-e826. PubMed ID: 27720689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India.
    Muniyandi M; Lavanya J; Karikalan N; Saravanan B; Senthil S; Selvaraju S; Mondal R
    Int Health; 2021 Dec; 13(6):536-544. PubMed ID: 33570132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing diagnostic networks to increase patient access to TB diagnostic services: Development of the diagnostic network optimization (DNO) approach and learnings from its application in Kenya, India and the Philippines.
    Albert H; Rupani S; Masini E; Ogoro J; Kamene M; Geocaniga-Gaviola D; Sistoso E; Garfin C; Chadha S; Kumar N; Kao K; Katz Z
    PLoS One; 2023; 18(11):e0279677. PubMed ID: 38033120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States.
    Menzies NA; Bellerose M; Testa C; Swartwood NA; Malyuta Y; Cohen T; Marks SM; Hill AN; Date AA; Maloney SA; Bowden SE; Grills AW; Salomon JA
    Am J Respir Crit Care Med; 2020 Dec; 202(11):1567-1575. PubMed ID: 32645277
    [No Abstract]   [Full Text] [Related]  

  • 30. Tuberculosis active case finding in Cambodia: a pragmatic, cost-effectiveness comparison of three implementation models.
    James R; Khim K; Boudarene L; Yoong J; Phalla C; Saint S; Koeut P; Mao TE; Coker R; Khan MS
    BMC Infect Dis; 2017 Aug; 17(1):580. PubMed ID: 28830372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing disease specific catastrophic cost estimates using longitudinal and cross-sectional designs: The example of tuberculosis.
    Yamanaka T; Castro MC; Ferrer JP; Cox SE; Laurence YV; Vassall A
    Soc Sci Med; 2024 Mar; 344():116631. PubMed ID: 38308959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Catastrophic Costs among Tuberculosis-Affected Households in Egypt: Magnitude, Cost Drivers, and Coping Strategies.
    Ghazy RM; Sallam M; Ashmawy R; Elzorkany AM; Reyad OA; Hamdy NA; Khedr H; Mosallam RA
    Int J Environ Res Public Health; 2023 Feb; 20(3):. PubMed ID: 36768005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
    van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
    BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of decentralised care model for managing MDR-TB in India.
    John D; Chatterjee P; Murthy S; Bhat R; Musa BM
    Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moving away from the "unit cost". Predicting country-specific average cost curves of VMMC services accounting for variations in service delivery platforms in sub-Saharan Africa.
    Bautista-Arredondo S; Pineda-Antunez C; Cerecero-Garcia D; Cameron DB; Alexander L; Chiwevu C; Forsythe S; Tchuenche M; Dow WH; Kahn J; Gomez GB; Vassall A; Bollinger LA; Levin C
    PLoS One; 2021; 16(4):e0249076. PubMed ID: 33886576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC).
    Brenzel L; Young D; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A13-20. PubMed ID: 25919153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of cost effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa.
    Floyd K; Wilkinson D; Gilks C
    BMJ; 1997 Nov; 315(7120):1407-11. PubMed ID: 9418087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costing the supply chain for delivery of ACT and RDTs in the public sector in Benin and Kenya.
    Shretta R; Johnson B; Smith L; Doumbia S; de Savigny D; Anupindi R; Yadav P
    Malar J; 2015 Feb; 14():57. PubMed ID: 25652315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.